Clinical Trials Logo

Filter by:
NCT ID: NCT01220947 Completed - Clinical trials for Hepatitis C, Chronic

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection

Start date: November 2010
Phase: Phase 2
Study type: Interventional

This randomized, open-label, active-controlled, parallel-group study will evaluate the sustained virological response of danoprevir boosted with low dose ritonavir in combination with Pegasys (peginterferon alfa-2a) and Copegus versus Pegasys and Copegus alone in treatment-naive patients with chronic Hepatitis C.

NCT ID: NCT01220505 Completed - Spinal Deformity Clinical Trials

Post Market Surveillance to Evaluate the Effectiveness the Polaris Deformity Spinal System

Start date: September 2010
Phase:
Study type: Observational

The purpose of this Post Market Surveillance Validation is to document the performance and clinical outcomes of the Polaris Deformity Spinal System & Trivium 3D Spinal Deformity Correction System.

NCT ID: NCT01218100 Completed - Clinical trials for Stage 2 Diastolic Hypertension

Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension

Start date: October 2010
Phase: Phase 4
Study type: Interventional

This study will evaluate the safety and efficacy of first-line treatment with a free combination (as two separate pills) of nebivolol and lisinopril in patients with stage 2 diastolic hypertension (DBP>= 100 mmHg).

NCT ID: NCT01217437 Completed - Clinical trials for Recurrent Medulloblastoma

Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

Start date: November 22, 2010
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well giving temozolomide and irinotecan hydrochloride together with or without bevacizumab works in treating young patients with recurrent or refractory medulloblastoma or central nervous system (CNS) primitive neuroectodermal tumors. Drugs used in chemotherapy, such as temozolomide and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether temozolomide and irinotecan hydrochloride are more effective with or without bevacizumab in treating medulloblastoma or CNS primitive neuroectodermal tumors.

NCT ID: NCT01216072 Completed - Clinical trials for Relapsing Forms of Multiple Sclerosis

A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis

EPOC
Start date: August 2010
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the change in patient-reported outcomes, physician assessment of a change as well as safety and tolerability in patients with Relapsing Forms of Multiple Sclerosis on previous Disease Modifying Therapy (DMT) who are randomized to one of two treatment arms: fingolimod vs. standard of care DMT.

NCT ID: NCT01215955 Completed - Clinical trials for Diabetes Mellitus, Type 2

Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes

AUTONOMY
Start date: December 2010
Phase: Phase 4
Study type: Interventional

Evidence regarding optimal methods of insulin dose adjustment is lacking in the literature. The purpose of this study is to evaluate the efficacy and safety of two approaches to escalate prandial insulin therapy in participants with type 2 diabetes mellitus not achieving adequate glycemic control on basal insulin.

NCT ID: NCT01215643 Completed - Chronic Pain Clinical Trials

Efficacy and Safety of DEB025 Alone or Combined With Either Ribavirin or Peg-IFN α2a in Chronic Hepatitis C Genotype 2 and 3 naïve Patients

Start date: October 2010
Phase: Phase 2
Study type: Interventional

The study is to investigate whether DEB025 alone or in combination with either ribavirin or peg-IFNα2a is more efficient compared to SOC in treatment-naïve patients with HCV genotype 2 and 3. In addition, triple therapy with DEB025 plus SOC will be applied to patients not achieving RVR in the different arms.

NCT ID: NCT01209325 Completed - Anal Cancer Clinical Trials

Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males

Start date: June 28, 2011
Phase: Phase 2
Study type: Interventional

RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective immune response to prevent viral infection. PURPOSE: This phase II trial is studying how well vaccine therapy works in preventing human papillomavirus (HPV) infection in young HIV-positive male patients who have sex with males.

NCT ID: NCT01207115 Completed - Clinical trials for Osteoarthritis of the Knee

A Study of ABT-652 in Adults With Osteoarthritis Pain of the Knee

Start date: September 2010
Phase: Phase 2
Study type: Interventional

To compare the analgesic efficacy and safety of ABT-652 administered twice daily (BID) to placebo in subjects with osteoarthritis (OA) of the knee.

NCT ID: NCT01206556 Completed - Clinical trials for Papilloma Virus, Human

IMPAACT P1085: Human Papilloma Virus (HPV) Type-Specific Antibody

HPV
Start date: May 2010
Phase: N/A
Study type: Observational

This study is being done to evaluate how long the immune response from the Human Papilloma Virus (HPV) vaccine you / your child received persists. The immune response occurred after immunization and is what protects you/your child from HPV disease. You / your child received this vaccine as part of an earlier study (P1047). The vaccine is called Human Papillomavirus Vaccine (QHPV Vaccine, also known as GARDASIL®). The study will check to see if the protective effects (called "antibodies") produced by the vaccine have lasted, and for how long these effects will continue to last. You will not be given any medications or vaccines as part of this follow-up study.